Evaluation of alendronate in prevention of steroid- induced osteopenia in childhood ALL and NH

Phase 2

• Conditions: Condition 1: Acute lymphoblastic leukaemia. Condition 2: Non-Hodgkin lymphoma. Condition 3: osteoprosis.; Acute lymphoblastic leukaemia; Non-Hodgkin lymphoma, unspecified; Drug-induced osteoporosis

• Registration Number: IRCT201202279155N1
• Lead Sponsor: Vice chancellor for research,Arak University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

inclusion criteria: children with ALL or NHL; informed consent form
exclusion criteria: Patient or parents desire to leave the study; Non-compliance with treatment regimen

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
BMD. Timepoint: 0, 6months after drug administration. Method of measurement: Bone densitometery of neck of femur and spins.

Secondary Outcome Measures

Name	Time	Method
Sever allergic reaction. Timepoint: every week. Method of measurement: history and physical examination.;Gastro intestinl problems. Timepoint: every week. Method of measurement: history and physical examination.